Translate
Subscribe to Blog via Email
Ronny Allan
Perspective Therapeutics Announces First Neuroendocrine Tumor Patients Dosed with Therapeutic Intent
SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announced today that the first patient was dosed at Washington University in St Louis in the Company’s Phase 1/2a trial evaluating the safety and efficacy of [212Pb]VMT-α-NET, a targeted alpha-particle therapy (TAT), in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs) – including Pheochromoctyomas and Paragangliomas and metatatic Neuroendocrine Carcinomas where applicable.
The trial is a multi-center, open-label dose escalation, dose expansion study of [212Pb]VMT-α-NET in patients who have not received prior peptide receptor radionuclide therapy (PRRT). Read announcement here
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (212-Pb-VMT)
The Company’s melanoma (VMT01) and neuroendocrine tumour (VMT-𝛼-NET) programs will then commence Phase 1/2a therapy trials for the treatment of metastatic melanoma and neuroendocrine tumours at two leading academic institutions. The Company has also developed a proprietary lead-212 generator to secure isotope supply for clinical trials and commercial operations.
See clinical trial info below.
Locations;
Clinical Trial Document can be viewed by clicking here
Other timeline events
Update 23 January 2023
No acute adverse reactions were observed in the first 10 days post administration and patients remain stable and in good condition
No acute adverse reactions were observed in the first 10 days post administration and patients remain stable and in good condition
Update 3 October 2023
An announcement from Viewpoint Molecular Targeting indicates the U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of [212Pb]VMT-α-NET for treatment of patients with SSTR2-positive unresectable or metastatic neuroendocrine tumors (NETs) (including GEP-NETs or bronchial NETs and pheochromocytomas and paragangliomas).
This does not mean the drug is approved for routine use, it just means the drug development has been given special treatment based on closer collaboration with FDA to ensure a smoother path when required. Clearly the drug still needs to meet FDA criteria along the way.
Update 23 January 2023
No acute adverse reactions were observed in the first 10 days post administration and patients remain stable and in good condition
No acute adverse reactions were observed in the first 10 days post administration and patients remain stable and in good condition
Update 10 September 2021
Viewpoint Molecular Targeting (TM) Receives FDA Clearance of Investigational New Drug Application for Phase 1 Imaging Study for VMT-a-NET for Neuroendocrine Tumors
Edit: This is now delayed. The Phase 0 imaging trial precedes the therapy trial
Alpha-emitter PRRT
Some years ago I wrote about an emerging type of peptide receptor radionuclide therapy (PRRT) suggesting it could be next generation. That work continues. It was being labelled with the term “Targeted Alpha-emitter Therapy (TAT)” using “alpha particles”. The current approved types of PRRT use beta particles so is a totally different method. You might be thinking what the differences are and how does it affect me? You can read more in my article PRRT – The Sequel? – Targeted Alpha-emitter Therapy (TAT).
I also wrote about the term THERANOSTICS, a combo term for THERAPY and DIAGNOSTICS. In the same way that you have a theranostic pair in Ga68 PET and Lu177 DOTATATE/DOTATOC, alpha particle therapy will eventually need the same approach in order that specialists know the output from the diagnostic imaging, will have a therapeutic effect using alpha therapy.
So, it is good to see trials emerging along these lines. VMT-𝛼-NET is entering a Phase 0 imaging study followed by a Phase 1 therapy study for neuroendocrine tumours at the University of Iowa.
VMT = Viewpoint Molecular Targeting (now Perspective Therapeutics)
Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Company’s proprietary technology utilizes lead-212 (i.e. 212Pb mentioned in the TAT article above) to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. Viewpoint is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This ‘theranostic’ approach enables the ability to see the specific tumour and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.
VMT-𝛼-NET is designed to deliver powerful alpha particle radiation specifically to the NET, while minimizing risk to normal organs and tissues. In 2019, the University of Iowa was awarded an R01 research grant from the National Cancer Institute (NCI) to prepare for and conduct an image-guided alpha-particle therapy trial of VMT-𝛼-NET for NETs. The first-in-human imaging trial was anticipated to commence in early 2021 but in April 2022, I don’t believe the trial linked below was commenced (to be confirmed). Viewpoint has further been awarded over $4M in the form of Small Business Innovation Research grants from the NCI to advance this cutting-edge treatment to clinical development. Thus, the VMT-𝛼-NET receptor-targeted alpha-particle radiotherapy is positioned to advance a new transformative treatment paradigm for NET patients.
A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent is a stepping stone to therapy trials.
This is the first-in-human study to determine if [203Pb]VMT-α-NET identifies neuroendocrine tumors with SPECT/CT. This is the first step to testing [212Pb]-based alpha radiation therapy in neuroendocrine therapy. Details of this clinical trial can be found here.
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (212-Pb-VMT) – Clinical Trial document
Clinical Trial Document can be viewed by clicking here
Disclaimer
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
General Clinical Trials Disclaimer
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact. If you need questions, the articles here is very useful Questions to Ask About Clinical Trials | Cancer.Net
The inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan.
Finally
Whenever I post about a trial or study, some people get excited without understanding that these new treatments and capabilities can very often take years to come to fruition and it’s also possible that clinical trials can be halted, or that national approval agencies will not approve the final product. Plus, not everyone will be eligible, so always check the exclusion and inclusion criteria in the relevant clinical trials document. Please bear that in mind when reading studies/clinical trials posted on RonnyAllan.NET
Top 10 Posts & Pages in the last 48 hours (auto updates) (Click the titles to read them)
Thanks for reading.
Personal Facebook. Like this page please.
Blog Facebook. Like this page please.
Awareness Facebook Like this page please.
Sign up for my newsletters – Click Here
My Diagnosis and Treatment History
Check out my online presentations
Check out my WEGO Health Awards
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
Surgery for NETs – Chop Chop
May 2024. a refurbish from some of my early work in 2015. I’m fairly sure not a lot has changed in surgery over the years.
A Review of April 2024 on RonnyAllan.NET
Here is the monthly summary of what we all achieved in April 2024. Something new, something blue and some borrowed too! Every share helps someone
I’m only as good as my last scan
“I’m only as good as my last scan”. I once received this comment in response to one of my posts. I thought it was a
Happy 10th birthday to my Blog Ronny Allan – Living with Neuroendocrine Cancer (RonnyAllan.NET)
On 29th April 2014, I release my first post entitled “What’s it all about” i.e. why on earth am I writing a blog! It was
Neuroendocrine – what’s that?
I once met some fellow cancer advocates and the conversation turned to what inspired us to ‘do what we do’. When it came to my
The trouble with the NET (Part 2) – Alternative Therapies – what’s the harm?
But it works, I read it on the internet! “But it works… I read it on the internet!”You may remember my article entitled The trouble
‘Chinese Dumplings’ and Neuroendocrine Cancer
Update of one of my posts from 2015 which was interesting in that year. This is not really about a treatment which is available everywhere
“An odd disposition of tumours” – less common metastases in Small Intestine and Pancreatic NETs
Every day is a learning day in NET! When I was diagnosed in 2010, my Oncologist sent me for a specialist scan that would help
Chemotherapy for Neuroendocrine Cancer
Edited and checked April 2024One of the unusual aspects of Neuroendocrine Cancer is that chemotherapy is not normally considered as a ‘standard of care’ or
A cup of tea
I would also mention those who contributed to my “Tea Fund” which resides on PayPal. You don’t need a PayPal account as you can select a card but don’t forget to select the number of units first (i.e. 1 = £4, 2 = £8, 3 = £12, and so on), plus further on, tick a button to NOT create a PayPal account if you don’t need one. Clearly, if you have a PayPal account, the process is much simpler
Through your generosity, I am able to keep my sites running and provide various services for you. I have some ideas for 2023 but they are not detailed enough to make announcements yet.
This screenshot is from every single post on my website and depending on which machine you are using, it will either be top right of the post or at the bottom (my posts are often long, so scroll down!)
Related
Discover more from Ronny Allan - Living with Neuroendocrine Cancer
Subscribe to get the latest posts to your email.
Do you know what centres in the US or Europe are currently running clinical research trials with TAT ?
Not 100% sure but likely to be Excel Houston in USA and in Germany possibly wherever Professor Richard Baum works.
[…] Neuroendocrine Tumour (VMT-𝛼-NET) programs Ronny Allan – Living with Neuroendocrine Cancer May 10 2021 […]